Modality
ADC
MOA
CDK4/6i
Target
EZH2
Pathway
PD-1/PD-L1
MesoFabryPSP
Development Pipeline
Preclinical
~Feb 2013
→ ~May 2014
Phase 1
~Aug 2014
→ ~Nov 2015
Phase 2
~Feb 2016
→ ~May 2017
Phase 3
Aug 2017
→ May 2029
Phase 3Current
NCT07308482
2,012 pts·PSP
2021-01→2027-07·Recruiting
NCT03648421
2,887 pts·Fabry
2017-12→2029-05·Recruiting
NCT08590892
1,019 pts·Meso
2017-08→2028-01·Recruiting
5,918 total pts3 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2027-07-091.3y awayPh3 Readout· PSP
2028-01-051.8y awayPh3 Readout· Meso
2029-05-073.1y awayPh3 Readout· Fabry
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P3
Recruit…
P3
Recruit…
P3
Recruit…
Catalysts
Ph3 Readout
2027-07-09 · 1.3y away
PSP
Ph3 Readout
2028-01-05 · 1.8y away
Meso
Ph3 Readout
2029-05-07 · 3.1y away
Fabry
Recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07308482 | Phase 3 | PSP | Recruiting | 2012 | FEV1 |
| NCT03648421 | Phase 3 | Fabry | Recruiting | 2887 | Mayo |
| NCT08590892 | Phase 3 | Meso | Recruiting | 1019 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| NBI-3153 | Neurocrine | Approved | Aβ |